Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W; CaMos Research Group.

Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10. Erratum in: Am J Gastroenterol. 2013 Jan;108(1):157.

PMID:
22777336
2.

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

Targownik LE, Lix LM, Leung S, Leslie WD.

Gastroenterology. 2010 Mar;138(3):896-904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.

PMID:
19931262
3.

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.

Osteoporos Int. 2012 Jan;23(1):277-84. doi: 10.1007/s00198-011-1574-5. Epub 2011 Mar 2.

PMID:
21365461
4.

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z.

Arch Intern Med. 2010 May 10;170(9):765-71. doi: 10.1001/archinternmed.2010.94.

5.

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.

Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group.

Osteoporos Int. 2013 Apr;24(4):1161-8. doi: 10.1007/s00198-012-2112-9. Epub 2012 Aug 14.

PMID:
22890365
6.

Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women.

Bruyere O, Varela AR, Adami S, Detilleux J, Rabenda V, Hiligsmann M, Reginster JY.

Eur J Epidemiol. 2009;24(11):707-12. doi: 10.1007/s10654-009-9381-4. Epub 2009 Aug 29.

PMID:
19728118
7.

Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study.

Jamal SA, Goltzman D, Hanley DA, Papaioannou A, Prior JC, Josse RG.

Osteoporos Int. 2009 May;20(5):737-44. doi: 10.1007/s00198-008-0727-7. Epub 2008 Sep 18.

PMID:
18800179
8.

Accelerated bone mineral loss following a hip fracture: a prospective longitudinal study.

Dirschl DR, Henderson RC, Oakley WC.

Bone. 1997 Jul;21(1):79-82.

PMID:
9213011
9.

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.

Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY.

J Clin Endocrinol Metab. 2007 Aug;92(8):3076-81. Epub 2007 Jun 12.

PMID:
17566094
10.

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

Solomon DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA, Finkelstein JS.

J Bone Miner Res. 2015 Feb;30(2):232-9. doi: 10.1002/jbmr.2344.

11.

Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.

Takakuwa M, Iwamoto J, Itabashi K.

Clin Drug Investig. 2012 Feb 1;32(2):121-9. doi: 10.2165/11597990-000000000-00000.

PMID:
22185631
12.

Physical activity, body mass index and bone mineral density-associations in a prospective population-based cohort of women and men: the Canadian Multicentre Osteoporosis Study (CaMos).

Langsetmo L, Hitchcock CL, Kingwell EJ, Davison KS, Berger C, Forsmo S, Zhou W, Kreiger N, Prior JC; Canadian Multicentre Osteoporosis Study Research Group.

Bone. 2012 Jan;50(1):401-8. doi: 10.1016/j.bone.2011.11.009. Epub 2011 Nov 30.

13.

Fracture risk and bone mineral density reduction associated with proton pump inhibitors.

Lau YT, Ahmed NN.

Pharmacotherapy. 2012 Jan;32(1):67-79. doi: 10.1002/PHAR.1007. Review.

PMID:
22392829
14.

Fracture prediction from bone mineral density in Japanese men and women.

Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M.

J Bone Miner Res. 2003 Aug;18(8):1547-53.

15.

Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos).

Tenenhouse A, Joseph L, Kreiger N, Poliquin S, Murray TM, Blondeau L, Berger C, Hanley DA, Prior JC; CaMos Research Group.Canadian Multicentre Osteoporosis Study.

Osteoporos Int. 2000;11(10):897-904.

PMID:
11199195
16.

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD.

J Bone Miner Res. 2002 Jan;17(1):1-10.

17.

Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate.

Bruyère O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY.

Curr Med Res Opin. 2007 Dec;23(12):3041-5.

PMID:
17967221
18.

Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.

Fournier MR, Targownik LE, Leslie WD.

Maturitas. 2009 Sep 20;64(1):9-13. doi: 10.1016/j.maturitas.2009.07.006. Epub 2009 Aug 11. Review.

PMID:
19674854
19.

Femoral neck bone loss predicts fracture risk independent of baseline BMD.

Nguyen TV, Center JR, Eisman JA.

J Bone Miner Res. 2005 Jul;20(7):1195-201. Epub 2005 Feb 21.

20.

Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.

Fraser LA, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi JD, Papaioannou A, Josse R, Kovacs CS, Olszynski WP, Towheed T, Hanley DA, Kaiser SM, Prior J, Jamal S, Kreiger N, Brown JP, Johansson H, Oden A, McCloskey E, Kanis JA, Leslie WD; CaMos Research Group.

Osteoporos Int. 2011 Mar;22(3):829-37. doi: 10.1007/s00198-010-1465-1. Epub 2010 Dec 16.

PMID:
21161508
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk